- CAS No.: 59803-98-4
- Type: Ophthalmic
Brimonidine Tartrate IUPSC name :
5-Bromo-N-(4, 5-dihydro-1H-imidazol-2-yl) quinoxalin-6-amine
Brimonidine is a α2-adrenergic receptor agonist. Alpha 2 agonists, through the activation of the Gi GPCR, inhibit the production of acetylcholine. This reduces cAMP and hence Aqueous Humor production by the ciliary body.
Description: Brimonidine Tartrate Ophthalmic Solution 0.2% is a relatively selective alpha-2 adrenergic agonist for ophthalmic use. In solution, brimonidine tartrate ophthalmic solution 0.2% has a clear, greenish-yellow color. It has an osmolality of 280-330 mOsml/kg and a pH of 5.6-6.6
Physico-chemical properties :
Chemical data Formula: C11H10BrN5.C4H6O6
Mol. Mass: 292.135 g/mol (442.24 as the tartrate salt)
Physical properties Appearance, color and odor: cream-light yellow powder, or off- white, odorless, crystalline solid. Melting point: C Solubility: the solubility of brimonidine tartrate in a variety of°207-208 C) Soluble in water, slightly soluble in°solvents at room temperature (≈25 methanol
Clinical uses :
Clinical uses Brimonidine is indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Mechanism of Action: Brimonidine tartrate ophthalmic solution 0.2% is an alpha adrenergic receptor agonist. It has a peak ocular hypotensive effect occurring at two hours post-dosing.
Clinical Evaluations :
Clinical Evaluations Elevated IOP presents a major risk factor in glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss. Brimonidine tartrate has the action of lowering intraocular pressure with minimal effect on cardiovascular and pulmonary parameters.
|Buyer||Product Name||Price||Quantity||Order Time(GMT+8)|